Study the effects of PLGA-PEG encapsulated Amphotericin B nanoparticle drug delivery system against Leishmania donovani
Study the effects of PLGA-PEG encapsulated Amphotericin B nanoparticle drug delivery system against Leishmania donovani
复制标题
DOI：
10.3109/10717544.2014.891271
复制
发表时间：
2015-05-01
期刊：
影响因子：
6
通讯作者：
Das, Pradeep
中科院分区：
文献类型：
--
作者：
Kumar, Rishikesh;Sahoo, Ganesh Chandra;Das, Pradeep
药物传递系统是一种很有前途的技术，可以提高化合物的溶解度和生物利用度。因此，我们开发了PLGA-PEG封装两性霉素B纳米颗粒（NPs）给药技术，以提高两性霉素B的溶解度，并在内脏利什曼病期间靶向感染组织的巨噬细胞。通过透射电子显微镜和动态光散射对该粒子进行了结构表征，结果表明该粒子的纳米尺寸为30-35纳米。傅里叶变换红外光谱证实了PLGA-PEG的封装。PLGA-PEG包膜两性霉素B细胞外promastigote的平均细胞毒性（0.0803 + 0.0253）明显低于两性霉素B(0.1134 + 0.0153)，对脾组织中amastigotes的抑制作用明显高于常规两性霉素B（93.02 + 6.63比74.42 + 14.78）。在体外和体内研究中发现，两性霉素B包封的PLGA-PEG纳米颗粒的治疗效果优于游离两性霉素B。
Drug delivery systems are a promising technology to increase poor solubility and bioavailability of compounds. Therefore we have developed PLGA-PEG encapsulated amphotericin B nanoparticles (NPs) drug delivery technology to increase the solubility of amphotericin B and target the macrophage of infected tissues during visceral leishmaniasis. The structural characterization by transmission electron microscopy and dynamic light scattering revealed the nano-size of the particle (30-35 nanometers). Fourier transform infrared spectroscopy confirmed the PLGA-PEG encapsulation. The mean cytotoxic assay (0.0803 + 0.0253) of extracellular promastigote of PLGA-PEG encapsulated amphotericin B is significantly lower than that of amphotericin B (0.1134 + 0.0153) and inhibition of amastigotes in the splenic tissue was significantly more than with conventional amphotericin B (93.02 + 6.63 versus 74.42 + 14.78). Amphotericin B encapsulated PLGA-PEG nanoparticles were found to be more effective than free amphotericin B in terms of therapeutic efficacy during in vitro and in vivo study.